A Randomized, Open-label Study of the Achievement of a Mycophenolic Acid Therapeutic Window During Treatment With 2 Dosing Regimens of Oral CellCept Administered as a Component of Standard Immunosuppressive Therapy in Patients With Kidney Transplants

Trial Profile

A Randomized, Open-label Study of the Achievement of a Mycophenolic Acid Therapeutic Window During Treatment With 2 Dosing Regimens of Oral CellCept Administered as a Component of Standard Immunosuppressive Therapy in Patients With Kidney Transplants

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs Mycophenolate mofetil (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms CLEAR
  • Sponsors Roche
  • Most Recent Events

    • 30 Aug 2009 Results presented at 14th Congress of the European Society for Organ Transplantation.
    • 03 Jun 2009 Results presented at ATC 2009.
    • 30 May 2009 Results presented at the American Transplant Congress -- 9th Joint Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top